By Fineline Cube Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for its independently developed Izalontamab brengitecan (iza-bren) has been formally accepted for review by China’s National Medical Products Administration (NMPA). This milestone establishes iza-bren as the world’s first EGFR×HER3 bispecific antibody-drug conjugate (ADC) to achieve NDA acceptance and the only EGFR×HER3 bispecific ADC in Phase III clinical trials globally.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA/CDE (China) |
| Application Type | New Drug Application (NDA) |
| Status | Formally accepted for review |
| Product | Izalontamab brengitecan (iza-bren) |
| Classification | First-in-class EGFR×HER3 bispecific ADC |
| Global Significance | World’s first EGFR×HER3 bispecific ADC with NDA acceptance |
Additional NDA Submissions Under Review
- Locally advanced or metastatic nasopharyngeal carcinoma
- Recurrent or metastatic esophageal squamous cell carcinoma
Product Profile & Innovation
- Molecule Type: EGFR×HER3 bispecific antibody-drug conjugate (ADC)
- Key Innovation: First-in-class dual-targeting approach combining EGFR and HER3 pathways
- Development Stage: Phase III clinical trials (only EGFR×HER3 bispecific ADC at this stage globally)
- Clinical Program: Over 40 clinical trials across China and United States
- Therapeutic Scope: Broad range of tumor types under evaluation
Regulatory Recognition & Designations
| Jurisdiction | Designation Type | Count | Significance |
|---|---|---|---|
| China (CDE) | Breakthrough Therapy | 7 | Accelerated development pathway |
| China (CDE) | Priority Review | 2 | Expedited regulatory review |
| U.S. (FDA) | Breakthrough Therapy | 1 | FDA expedited development program |
Strategic Market Positioning
- First-Mover Advantage: Unprecedented position as world’s first EGFR×HER3 bispecific ADC with NDA acceptance
- Dual Receptor Targeting: Simultaneous inhibition of EGFR and HER3 addresses tumor heterogeneity and resistance mechanisms
- ADC Platform Validation: Demonstrates Sichuan Biokin’s advanced antibody-drug conjugate capabilities
- Global Development: Parallel clinical programs in China and U.S. support worldwide commercial potential
Clinical Development Portfolio
The extensive clinical program spanning over 40 trials reflects the molecule’s broad therapeutic potential across multiple solid tumor indications. The simultaneous NDA acceptance for multiple tumor types demonstrates strong clinical data supporting efficacy across different cancer contexts.
Competitive Landscape Analysis
| Aspect | Competitive Position |
|---|---|
| EGFR×HER3 Targeting | Only bispecific ADC in this class globally |
| Phase III Status | Sole EGFR×HER3 bispecific ADC at late-stage development |
| Regulatory Momentum | Unprecedented combination of breakthrough and priority designations |
| Geographic Reach | Simultaneous development in China and U.S. markets |
Market Opportunity Assessment
- EGFR/HER3-Expressing Tumors: Large addressable patient populations across multiple cancer types
- ADC Market Growth: Global ADC market projected to exceed $20 billion by 2030
- China Oncology Market: Rapidly expanding market for innovative cancer therapies
- Premium Pricing Potential: First-in-class status supports significant pricing power
Next Steps & Timeline Expectations
- NDA Review Period: Standard 200-day review timeline with potential acceleration due to priority designations
- Potential Approval: Anticipated 2027 approval pending successful review completion
- Commercial Preparation: Manufacturing scale-up and commercial infrastructure development underway
- Additional Indications: Continued clinical development across remaining tumor types in pipeline
Strategic Implications for Sichuan Biokin
This NDA acceptance represents a transformative milestone for Sichuan Biokin, potentially establishing the company as a global leader in next-generation bispecific ADC technology. The world-first achievement validates the company’s innovative approach to dual-receptor targeting and positions iza-bren for significant commercial success.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to risks including regulatory decisions, clinical trial outcomes, and competitive dynamics.-Fineline Info & Tech